Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R61/R33 Clinical Trial Optional)
This grant supports clinical research on non-invasive brain stimulation for substance use disorders, aiming to identify targets and understand the neurobiological and behavioral responses that lead to reduced drug use, with potential for breakthroughs in SUD research.
This grant is no longer accepting proposals
National Institutes of Health has archived this opportunity.
Funder: National Institutes of Health
Due Dates: August 14, 2024 (Renewal/Resubmission/Revision) | January 16, 2025 (New) | August 14, 2025 (Renewal/Resubmission/Revision) | January 16, 2026 (New) | August 14, 2026 (Renewal/Resubmission/Revision)
Funding Amounts: Up to $600,000 direct costs for the R61 phase (2 years); R33 phase (up to 3 years) has no set limit but must reflect project needs; total project period up to 5 years.
Summary: Supports exploratory clinical research to identify and validate novel non-invasive brain stimulation targets and mechanistic responses relevant to substance use disorder treatment.
Key Information: Applications must include clear, quantitative milestones for R61-to-R33 transition; preliminary data are not required; foreign and domestic applicants eligible.
Description
This opportunity, offered by the National Institute on Drug Abuse (NIDA) at NIH, funds mechanistic clinical research on non-invasive brain stimulation (NIBS) for substance use disorders (SUD). The goal is to identify and validate novel NIBS targets and to characterize neurobiological, cognitive, and behavioral responses to NIBS that may precede clinical outcomes such as reduced craving or drug use. Projects are expected to be exploratory and developmental, with the potential for high risk but also high impact in advancing SUD treatment research.
The grant uses the R61/R33 Phased Innovation Award mechanism, supporting an initial R61 phase (up to 2 years) focused on feasibility and milestone achievement, followed by an R33 phase (up to 3 years) for further development and validation, contingent on successful completion of R61 milestones.
